Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Payables: 2023-2025

Historic Payables for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $3.5 million.

  • BioLineRx's Payables fell 44.70% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.4 million, marking a year-over-year decrease of 45.69%. This contributed to the annual value of $5.6 million for FY2024, which is 48.63% down from last year.
  • As of Q2 2025, BioLineRx's Payables stood at $3.5 million, which was down 26.17% from $4.7 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Payables registered a high of $10.9 million during Q4 2023, and its lowest value of $3.5 million during Q2 2025.
  • Its 3-year average for Payables is $6.6 million, with a median of $6.5 million in 2023.
  • Data for BioLineRx's Payables shows a peak YoY increase of 15.70% (in 2024) and a maximum YoY decrease of 48.63% (in 2024) over the last 5 years.
  • BioLineRx's Payables (Quarterly) stood at $10.9 million in 2023, then slumped by 48.63% to $5.6 million in 2024, then plummeted by 44.70% to $3.5 million in 2025.
  • Its Payables stands at $3.5 million for Q2 2025, versus $4.7 million for Q1 2025 and $5.6 million for Q4 2024.